Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TANNED study of aprepitant-etoposide pharmacokinetic interaction in testicular cancer
NL-OMON50969Phase 4Active, not recruiting
- Sponsor
- Ziekenhuisapotheek
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aprepitant and etoposide in testicular cancer and Germ Cell Testicular Cancer, sponsored by Ziekenhuisapotheek. Primary endpoint: Etoposide exposure. Started Aug 2021; status: active, not recruiting.
02
Drugs
aprepitantetoposide
03
Conditions
testicular cancerGerm Cell Testicular Cancer
Beyond the preview
Go deeper on NL-OMON50969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50969.